Back to top
more

Surmodics (SRDX)

(Delayed Data from NSDQ)

$41.80 USD

41.80
478,250

+0.02 (0.05%)

Updated Jul 23, 2024 04:00 PM ET

After-Market: $41.84 +0.04 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Surmodics Gets CE Mark for SurVeil Drug-Coated Balloon

by Zacks Equity Research

Surmodics' (SRDX) receipt of CE Mark for SurVeil DCB should boost the company's Medical Devices segment.

    Here's Why You Should Retain LHC Group (LHCG) Stock Now

    by Zacks Equity Research

    Investor confidence is high in LHC Group (LHCG), thanks to solid prospects

    Amedisys (AMED) Broadens Hospice Base With AseraCare Buyout

    by Zacks Equity Research

    Amedisys (AMED) expects AseraCare business to add greater scale to its existing nationwide network.

    Medtronic Alters ECMO Therapy on New FDA Rules for Coronavirus

    by Zacks Equity Research

    Medtronic (MDT), in response to the FDA's new guidance due to the coronavirus-led health emergency, has made temporary alterations to its cardiopulmonary product indications for use in ECMO therapy.

    Tandem Diabetes Rides on Control-IQ Amid Coronavirus Crisis

    by Zacks Equity Research

    Strong domestic pump sales and international expansion boosts sales of Tandem Diabetes (TNDM).

    Here's Why You Should Hold on to Tandem Diabetes Stock for Now

    by Zacks Equity Research

    Investors continue to be optimistic about Tandem Diabetes (TNDM) on robust pump sales and international growth.

    HEXO in Focus: Stock Moves 9% Higher

    by Zacks Equity Research

    HEXO saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

    QIAGEN Sales Grow on Coronavirus Solutions Ahead of Selloff

    by Zacks Equity Research

    QIAGEN (QGEN) ramps up production capacity of solutions currently being used for testing purposes.

    Here's Why You Should Add QIAGEN (QGEN) to Your Portfolio

    by Zacks Equity Research

    Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.

    Thermo Fisher (TMO) Partners With CSL to Expand Pharma Arm

    by Zacks Equity Research

    Thermo Fisher (TMO), through its alliance with CSL, expands Pharma Services arm to meet the rising demand for biologic therapies.

    Quest Diagnostics' Self-Collection Coronavirus Kit Gets EUA

    by Zacks Equity Research

    This kit by Quest Diagnostics (DGX) is suitable for use in children supervised by an adult.

    SurModics (SRDX) Up 1.1% Since Last Earnings Report: Can It Continue?

    by Zacks Equity Research

    SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    LabCorp Partners With Medable to Expand Technology Ecosystem

    by Zacks Equity Research

    LabCorp (LH) expands technology ecosystem to accelerate the adoption of decentralized clinical trials by collaborating with Medable.

    Zimmer Biomet Faces Procedure Delays, Long-Term Potential Solid

    by Zacks Equity Research

    Zimmer Biomet (ZBH) believes COVID-19 to continue to have a significant unfavorable impact on its sales in the near term.

    Here's Why You Should Hold on to Chemed (CHE) Stock for Now

    by Zacks Equity Research

    Investors continue to be optimistic about Chemed (CHE) on robust segmental growth.

    Teleflex (TFX) Rides on UroLift Sales Amid Coronavirus Mayhem

    by Zacks Equity Research

    NeoTract, the acquired business of Teleflex (TFX), continues to perform impressively.

    IDEXX Sees Higher Clinical Visits Despite Coronavirus Crisis

    by Zacks Equity Research

    IDEXX (IDXX) notes a significant improvement in U.S. clinical visit trends across major regions.

    Henry Schein Sales Drop on Coronavirus Woes, Costs Rise

    by Zacks Equity Research

    Henry Schein (HSIC) registers dismal performance within Dental business on suspension of non-emergency procedures in response to the pandemic.

    Medtronic Gets FDA Nod for Guardian CGM's Android Version

    by Zacks Equity Research

    Medtronic (MDT) expands reach to diabetic patients by introducing the Guardian Connect CGM system's Android version post its FDA clearance.

    Here's Why You Should Add Surmodics to Your Portfolio Now

    by Zacks Equity Research

    Investor confidence is high in Surmodics (SRDX) stock, thanks to solid prospects.

    Here's Why You Should Hold on to Edwards Lifesciences for Now

    by Zacks Equity Research

    Investors continue to be optimistic about Edwards Lifesciences (EW) on robust demand for products and a promising surgical structural heart business.

    Medtronic Launches Kyphon Cannula for Balloon Kyphoplasty

    by Zacks Equity Research

    Medtronic's (MDT) new cannula will complement its entire portfolio of balloon kyphoplasty products, including Kyphon Xpander II Inflatable Bone Tamps.

    Here's Why You Should Hold on to Illumina (ILMN) Stock for Now

    by Zacks Equity Research

    Investors continue to be optimistic about Illumina (ILMN) on its focus on partnerships and robust demand for its products.

    ResMed (RMD) Launches Digital Tool for Remote Mask Selection

    by Zacks Equity Research

    Based on a brief questionnaire remotely filled by the patient, the MaskSelector tool recommends the best suitable ResMed (RMD) mask for patients.

      Neogen (NEOG) Introduces Upgraded Igenity Beef Genomic Profile

      by Zacks Equity Research

      Neogen (NEOG) looks to provide better technology and information to commercial beef producers to take better decisions for their profitability.